title: Efavirenz urolithiasis.
authors.forename: Hassane
authors.initials: H
authors.lastname: Izzedine
authors.forename: Marc Antoine
authors.initials: MA
authors.lastname: Valantin
authors.forename: Michel
authors.initials: M
authors.lastname: Daudon
authors.forename: Hocine Ait
authors.initials: HA
authors.lastname: Mohand
authors.forename: Fabienne
authors.initials: F
authors.lastname: Caby
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
mesh_terms: D000480:Alkynes; D000069446:Atazanavir Sulfate; D048588:Benzoxazines / Q000009:adverse effects*; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects; D052878:Urolithiasis / Q000139:chemically induced*
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D000069446:Atazanavir Sulfate; C098320:efavirenz; D019438:Ritonavir